Literature DB >> 24798573

Issues in trial design for ANCA-associated and large-vessel vasculitis.

Ruth M Tarzi1, Justin C Mason1, Charles D Pusey2.   

Abstract

Randomized clinical trials (RCTs) have informed the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, although challenges still exist. The evidence base for treating large-vessel vasculitis (LVV) is weaker, but initiatives to standardize diagnostic criteria and outcome measures, and to validate biomarkers in LVV, together with newly initiated RCTs should start to address this need. In this Perspectives, we discuss the prerequisites for RCTs in vasculitis, existing trial evidence, continuing unmet needs, potential therapeutic avenues to explore and considerations in the design of future trials.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24798573     DOI： 10.1038/nrrheum.2014.67

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  63 in total

1.  EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis.

Authors:  Neil Basu; Richard Watts; Ingeborg Bajema; Bo Baslund; Thorsten Bley; Maarten Boers; Paul Brogan; Len Calabrese; Maria C Cid; Jan Willem Cohen-Tervaert; Luis Felipe Flores-Suarez; Shouichi Fujimoto; Kirsten de Groot; Loic Guillevin; Gulen Hatemi; Thomas Hauser; David Jayne; Charles Jennette; Cees G M Kallenberg; Shigeto Kobayashi; Mark A Little; Alfred Mahr; John McLaren; Peter A Merkel; Seza Ozen; Xavier Puechal; Niels Rasmussen; Alan Salama; Carlo Salvarani; Caroline Savage; David G I Scott; Mårten Segelmark; Ulrich Specks; Cord Sunderköetter; Kazuo Suzuki; Vladimir Tesar; Allan Wiik; Hasan Yazici; Raashid Luqmani
Journal:  Ann Rheum Dis       Date:  2010-05-06       Impact factor: 19.103

2.  ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS).

Authors:  Anthea Craven; Joanna Robson; Cristina Ponte; Peter C Grayson; Ravi Suppiah; Andrew Judge; Richard Watts; Peter A Merkel; Raashid A Luqmani
Journal:  Clin Exp Nephrol       Date:  2013-08-31       Impact factor: 2.801

3.  Preparing for responsible sharing of clinical trial data.

Authors:  Michelle M Mello; Jeffrey K Francer; Marc Wilenzick; Patricia Teden; Barbara E Bierer; Mark Barnes
Journal:  N Engl J Med       Date:  2013-10-21       Impact factor: 91.245

Review 4.  Takayasu arteritis--advances in diagnosis and management.

Authors:  Justin C Mason
Journal:  Nat Rev Rheumatol       Date:  2010-07       Impact factor: 20.543

5.  Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades.

Authors:  Julia U Holle; Wolfgang L Gross; Ute Latza; Bernhard Nölle; Petra Ambrosch; Martin Heller; Regina Fertmann; Eva Reinhold-Keller
Journal:  Arthritis Rheum       Date:  2011-01

Review 6.  Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literature.

Authors:  Cloé Comarmond; Emmanuel Plaisier; Karine Dahan; Tristan Mirault; Joseph Emmerich; Zahir Amoura; Patrice Cacoub; David Saadoun
Journal:  Autoimmun Rev       Date:  2011-12-04       Impact factor: 9.754

7.  Etanercept plus standard therapy for Wegener's granulomatosis.

Authors: 
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

8.  Long-term patient survival in ANCA-associated vasculitis.

Authors:  Oliver Flossmann; Annelies Berden; Kirsten de Groot; Chris Hagen; Lorraine Harper; Caroline Heijl; Peter Höglund; David Jayne; Raashid Luqmani; Alfred Mahr; Chetan Mukhtyar; Charles Pusey; Niels Rasmussen; Coen Stegeman; Michael Walsh; Kerstin Westman
Journal:  Ann Rheum Dis       Date:  2010-11-24       Impact factor: 19.103

9.  Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial.

Authors:  J A Jover; C Hernández-García; I C Morado; E Vargas; A Bañares; B Fernández-Gutiérrez
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

10.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

Authors:  R A Luqmani; P A Bacon; R J Moots; B A Janssen; A Pall; P Emery; C Savage; D Adu
Journal:  QJM       Date:  1994-11
View more
  3 in total

1.  Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy.

Authors:  Berit Dalsgaard Nielsen; Lars Christian Gormsen; Ib Tønder Hansen; Kresten Krarup Keller; Philip Therkildsen; Ellen-Margrethe Hauge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-18       Impact factor: 9.236

Review 2.  Large-vessel vasculitis.

Authors:  Dan Pugh; Maira Karabayas; Neil Basu; Maria C Cid; Ruchika Goel; Carl S Goodyear; Peter C Grayson; Stephen P McAdoo; Justin C Mason; Catherine Owen; Cornelia M Weyand; Taryn Youngstein; Neeraj Dhaun
Journal:  Nat Rev Dis Primers       Date:  2022-01-06       Impact factor: 65.038

3.  Randomized clinical trials in ANCA-associated vasculitis: a systematic analysis of the WHO - International Clinical Trials Registry Platform.

Authors:  Michele Iudici; Xavier Puéchal; Alejandro Brigante; Ignacio Atal; Cem Gabay
Journal:  Orphanet J Rare Dis       Date:  2020-05-29       Impact factor: 4.123
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.